CT肺动脉造影中的对比剂监测技术:乳腺剂量中一个重要但被低估的贡献因素
单中心回顾性研究比较80kV与120kV对比剂监测方案对乳腺剂量的影响,纳入非妊娠女性221例(80kV)与281例(120kV),妊娠女性99例单独分析。120kV监测占乳腺总剂量27%,80kV组仅7%;监测所致乳腺剂量在非妊娠组降低79%(0.36mGy±0.37 vs 1.7mGy±1.02,p<0.001),妊娠组降低88%(0.25mGy±0.67 vs 2.24mGy±1.61,p<0.001),CTPA诊断质量与时机无统计学差异。
要点
- 120kV对比剂监测可占CTPA乳腺总剂量的27%,80kV监测方案下仅占7%。
- 监测所致乳腺剂量非妊娠组降低79%(0.36mGy±0.37 vs 1.7mGy±1.02,p<0.001)。
- 妊娠组监测乳腺剂量降低88%(0.25mGy±0.67 vs 2.24mGy±1.61,p<0.001)。
核心结论
- 将对比剂监测部分的管电压从120kV降至80kV,可在不影响CTPA诊断质量或时机的前提下显著降低妊娠与非妊娠女性患者的乳腺剂量。
研究设计与样本
- 单中心回顾性研究,采用Siemens Somatom Definition AS+设备,80kV对比剂监测CTPA方案组221例女性患者与常规120kV监测方案组281例女性患者比较,其中99例妊娠患者单独分析,使用ImPACT剂量学软件计算剂量,并对分组子集评估CTPA诊断质量。
诊断标准与关键数值
- 120kV标准方案下对比剂监测部分占CTPA乳腺总剂量的27%,80kV研究组仅占7%。
- 非妊娠患者监测部分乳腺剂量0.36mGy±0.37 vs 1.7mGy±1.02,降低79%(p<0.001)。
- 妊娠患者监测部分乳腺剂量0.25mGy±0.67 vs 2.24mGy±1.61,降低88%(p<0.001)。
- CTPA诊断质量或时机无统计学差异。
临床应用与阅片要点
- 阅片及报告时可关注CTPA对比剂监测扫描的管电压设置,因其可贡献乳腺总剂量的27%。
- 对妊娠及非妊娠女性患者,采用80kV对比剂监测方案可在不影响CTPA诊断质量与时机的情况下降低乳腺剂量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aims of our study were to evaluate the contribution of contrast-monitoring techniques to breast dose in pregnant and non-pregnant women, and to investigate the effect of a reduced peak kilovoltage (kV) monitoring scan protocol on breast dose and Computed Tomography Pulmonary Angiography (CTPA) diagnostic quality.
MATERIALS AND METHODS: Single center retrospective study of 221 female patients undergoing a reduced kV 80kV contrast-monitoring CTPA protocol compared to 281 patients using the conventional 120kV contrast-monitoring protocol (Siemens Somatom Definition AS+). 99 pregnant patients analyzed separately. ImPACT dosimetry software was used to calculate dose. Group subsets were evaluated to assess CTPA diagnostic quality.
RESULTS: The contrast-monitoring component of a CTPA study constituted 27% of the overall breast dose when using a standard 120kV protocol compared to only 7% of the overall breast dose in the 80kV study group. The dose to the breast from the contrast-monitoring component alone was reduced by 79% in the non-pregnant patients (0.36mGy±0.37 versus 1.7mGy±1.02; p<0.001), and by 88% in the pregnant population (0.25mGy±0.67 versus 2.24mGy±1.61; p<0.001). There was no statistical difference in CTPA diagnostic quality or timing.
CONCLUSION: Despite a short scan length and relatively small DLP, contrast-monitoring techniques (test-bolus or bolus-tracked) set at 120kV can account for 27% of the overall breast dose accrued from a CTPA study. By decreasing the kilovoltage of the contrast-monitoring component, a significant reduction in breast dose for pregnant and non-pregnant female patients can be achieved without affecting CTPA quality or timing.
引用
- Mitchell DP, Rowan M, Loughman E, et al. Contrast monitoring techniques in CT pulmonary angiography: An important and underappreciated contributor to breast dose. Eur J Radiol. 2016. PMID: 28027745. doi:10.1016/j.ejrad.2016.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。